A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 May 2018
At a glance
- Drugs Riluzole (Primary) ; Sorafenib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 15 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
- 05 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
- 10 Jun 2017 Biomarkers information updated